Guan, Xuesong

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., & Maggs, D. G. (2008) · Current Medical Research and Opinion

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 699

Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: A randomized, cross-over study

DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., & MacConell, L. (2008) · Current Medical Research and Opinion

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 373

Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials

Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., & Wintle, M. E. (2007) · Clinical Therapeutics

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 279